This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Baxter International (BAX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 6.85% and 1.45%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Lineup for Jan 31: EW, BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.
Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.
Baxter International (BAX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Core Renal Care Unit Fuel Baxter's (BAX) Q4 Earnings?
by Zacks Equity Research
Management at Baxter (BAX) expects Renal Care to see growth of 3-4% in 2018.
Will Core MedSurg Segment Aid Stryker's (SYK) Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) Q4 results are likely to be aided by its core MedSurg segment.
Stock Market News For Jan 18, 2019
by Zacks Equity Research
Benchmarks ended in the green on Thursday, extending the streak of gains to three days on the trot.
Baxter (BAX) Gains From Sharesource's Global Success Rates
by Zacks Equity Research
Baxter's (BAX) PD platform sees increased demand, owing to rising CKD rates around the world.
Will Instruments Fuel Intuitive Surgical (ISRG) Q4 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) top line in the fourth quarter of 2018 is likely to benefit from solid grow that the Instruments and Accessories segment.
Varian Medical (VAR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Strong overseas presence and product launches are likely to aid Varian Medical's (VAR) fiscal first-quarter results.
Stock Market News For Jan 8, 2019
by Zacks Equity Research
Wall Street rallied for the second consecutive day on Monday after resumption of trade related negotiations between the United States and China
Baxter's PD Solution to Treat Patients, Prospects Bright
by Zacks Equity Research
Baxter's (BAX) kidney care portfolio likely to favor the company as kidney care demand shoots up in the United States.
Can Baxter (BAX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Mallinckrodt's Inhaled Xenon Gas Therapy Enters Phase III
by Zacks Equity Research
Mallinckrodt (MNK) and partner NPXe Limited enrol the first patient in the phase III study on xenon gas for inhalation (XENEX) for Post Cardiac Arrest Syndrome (PCAS).
Stock Market News For Dec 19, 2018
by Zacks Equity Research
U.S. stocks closed mostly higher on Tuesday after a volatile session, reversing stiff decline in previous two trading days
Baxter Stock up on Launch of Disposable Curved Applicator
by Zacks Equity Research
Baxter's (BAX) wide array of surgical products see lucrative market prospects.
Here's Why You Should Hold Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.
Baxter & EFCNI Collaborate to Improve Care for Preterm Born
by Zacks Equity Research
Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.
Why Is Baxter (BAX) Up 7.9% Since Last Earnings Report?
by Zacks Equity Research
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up
by Zacks Equity Research
Baxter's (BAX) diversified surgical portfolio lends it a competitive edge in the MedTech space.
Company News For Nov 1, 2018
by Zacks Equity Research
Companies In The News Are: TMUS,S,K,BAX
Top Analyst Reports for Amazon, Facebook, Mastercard & Merck
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Amazon (AMZN), Facebook (FB), Mastercard (MA) and Merck (MRK).
Baxter (BAX) Earnings Beat, Revenues Lag Estimates in Q3
by Zacks Equity Research
Baxter (BAX) gains from Renal Care and Advanced Surgery units in Q3; APAC sales soft.
Baxter International (BAX) Tops Q3 Earnings Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 8.11% and -0.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Q3 Earnings on Oct 31: BAX, MASI & More
by Zacks Equity Research
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.